title: Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies.
abstract: BACKGROUND
  Adiponectin is an anti-inflammatory and potentially antiatherogenic molecule. Some recent reports suggest that tumour necrosis factor alpha (TNFalpha) blockade therapy increases circulating adiponectin levels, but data are sparse and inconsistent.
  
  
  METHODS
  Data from a double-blind placebo controlled study of onercept in 126 patients with psoriatic arthritis (PsA) and from pre- and post-adalimumab treatment in 171 patients with rheumatoid arthritis (RA) were used to examine the effect of TNFalpha blockade therapy on adiponectin.
  
  
  RESULTS
  Despite expected associations of adiponectin with gender and baseline high-density lipoprotein cholesterol and triglyceride, adiponectin levels did not change over time with TNFalpha blockade therapy in either group. The mean+/-SD absolute change in adiponectin levels was -0.23+/-4.6 microg/ml in patients with PsA treated with combined onercept 50 mg and onercept 100 mg (vs placebo, p=0.60) and 0.28+/-3.23 microg/ml in patients with RA treated with adalimumab (vs baseline, p=0.66).
  
  
  CONCLUSIONS
  These results do not support a significant effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease.
authors.affiliation: Department of Rheumatology, VU University Medical Center, Amsterdam, the Netherlands. mjl.peters@vumc.nl
authors.forename: Mike J L
authors.initials: MJ
authors.lastname: Peters
authors.forename: Pauline
authors.initials: P
authors.lastname: Watt
authors.forename: Lynne
authors.initials: L
authors.lastname: Cherry
authors.forename: Paul
authors.initials: P
authors.lastname: Welsh
authors.forename: Eric
authors.initials: E
authors.lastname: Henninger
authors.forename: Ben A C
authors.initials: BA
authors.lastname: Dijkmans
authors.forename: Iain B
authors.initials: IB
authors.lastname: McInnes
authors.forename: Michael T
authors.initials: MT
authors.lastname: Nurmohamed
authors.forename: Naveed
authors.initials: N
authors.lastname: Sattar
mesh_terms: D000068879:Adalimumab; D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000150:complications / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000209:etiology; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000494:pharmacology / Q000627:therapeutic use; D053319:Tumor Necrosis Factor Decoy Receptors / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D052242:Adiponectin; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D008055:Lipids; D047888:Receptors, Tumor Necrosis Factor, Type I; D053319:Tumor Necrosis Factor Decoy Receptors; D014409:Tumor Necrosis Factor-alpha; C069521:recombinant human tumor necrosis factor-binding protein-1; D000068879:Adalimumab